MedKoo product information:

 Toremifene Citrate

toremifene is a nonsteroidal triphenylethylene antiestrogen. Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM). This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity. Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

 FARESTON (toremifene citrate) Tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene. and the molecular formula is C26H28CINO • C6H8O7. The molecular weight of toremifene citrate is 598.10. The pKa is 8.0. Water solubility at 37°C is 0.63 mg/mL and in 0.02N HCI at 37°C is 0.38 mg/mL. FARESTON is available only as tablets for oral administration. Inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, and starch.

According to http://en.wikipedia.org/wiki/Toremifene, Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene. In 2007 GTx Inc. was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy(ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008. An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009.

 Mechanism of Action

Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly antiestrogenic in rats and humans and estrogenic in mice. In rats, toremifene causes regression of established dimethylbenzanthracene (DMBA)-induced mammary tumors. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene causes a decrease in the estradiol-induced vaginal cornification index in some postmenopausal women, indicative of its antiestrogenic activity. Toremifene also has estrogenic activity as shown by decreases in serum gonadotropin concentrations (FSH and LH). 

  1: Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. Epub 2009 Nov 10. Review. PubMed PMID: 19901958.

2: Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int. 2009 Apr;103(7):864-70. Review. PubMed PMID: 19302133.

3: Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009 Mar;55(3):533-42. Epub 2008 Nov 6. Review. PubMed PMID: 19013008.

4: Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008 Mar;63(3):163-81. Review. PubMed PMID: 18279543.

5: Sieber PR. Treatment of bicalutamide-induced breast events. Expert Rev Anticancer Ther. 2007 Dec;7(12):1773-9. Review. PubMed PMID: 18062751.

6: Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. Review. PubMed PMID: 17940447.

7: Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep;178(3 Pt 2):S9-S13. Epub 2007 Jul 20. Review. PubMed PMID: 17644117.

8: Musa MA, Khan MO, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14(11):1249-61. Review. PubMed PMID: 17504144.

9: Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24(5):361-79. Review. PubMed PMID: 17503894.

10: Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. Review. PubMed PMID: 17448265.

11: Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci. 2006 Dec;1092:374-84. Review. PubMed PMID: 17308162.

12: Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6315s-6319s. Review. PubMed PMID: 17062721.

13: Nozaki M. [SERM]. Nippon Rinsho. 2006 Sep;64(9):1645-50. Review. Japanese. PubMed PMID: 16972673.

14: Lewis-Wambi JS, Jordan VC. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis. 2005-2006;24:93-105. Review. PubMed PMID: 16917142.

15: Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc). 2006 Jun;42(6):355-67. Review. PubMed PMID: 16845439.

16: Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer. 2006 Feb;6 Suppl 2:S36-40. Review. PubMed PMID: 16595024.

17: Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6(3):181-202. Review. PubMed PMID: 16515478.

18: Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast. 2006 Oct;15(5):584-94. Epub 2006 Feb 28. Review. PubMed PMID: 16504510.

19: Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. Review. PubMed PMID: 16503765.

20: Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):503-10. Epub 2006 Feb 23. Review. PubMed PMID: 16500151.

21: Smith MR. Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol. 2005 Dec;2(12):608-15; quiz 628. Review. PubMed PMID: 16474548.

22: Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric. 2005 Sep;8(3):214-20. Review. PubMed PMID: 16390753.

23: Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast. 2006 Apr;15(2):142-57. Epub 2005 Nov 9. Review. PubMed PMID: 16289904.

24: Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89 Suppl 1:S9-S15. Review. PubMed PMID: 15770536.

25: Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005 Feb;41(3):346-56. Review. PubMed PMID: 15691633.

26: Morii H. [Safety profile of raloxifene]. Clin Calcium. 2004 Oct;14(10):100-4. Review. Japanese. PubMed PMID: 15577139.

27: Nozaki M. [Effects of raloxifene on other organs without bone: uterus]. Clin Calcium. 2004 Oct;14(10):55-60. Review. Japanese. PubMed PMID: 15577132.

28: Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev. 2004 Dec;30(8):695-706. Review. PubMed PMID: 15541579.

29: Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2004 Sep;40(9):751-64. Review. PubMed PMID: 15538548.

30: Gadducci A, Cosio S, Genazzani AR. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs. 2004 Oct;5(10):1031-44. Review. PubMed PMID: 15535424.

31: Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer. 2004 Sep;11(3):391-406. Review. PubMed PMID: 15369444.

32: Kim SY, Suzuki N, Laxmi YR, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev. 2004 May;36(2):199-218. Review. PubMed PMID: 15237851.

33: Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review. PubMed PMID: 14687597.

34: Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003 Oct 20;22(47):7316-39. Review. PubMed PMID: 14576841.

35: Eckhardt S. [Perspectives for the hormonal therapy of breast cancer]. Magy Onkol. 2003;47(2):133-40. Epub 2003 Sep 16. Review. Hungarian. PubMed PMID: 12975659.

36: Haskell SG. Selective estrogen receptor modulators. South Med J. 2003 May;96(5):469-76. Review. PubMed PMID: 12911186.

37: Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S105-15. Review. PubMed PMID: 12850531.

38: White IN. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003 Jun;4(3):223-39. Review. PubMed PMID: 12769667.

39: Steiner MS, Raghow S. Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J Urol. 2003 May;21(1):31-6. Epub 2003 Feb 14. Review. PubMed PMID: 12756492.

40: Vogel CL. Update on the current use of hormonals as therapy in advanced breast cancer. Anticancer Drugs. 2003 Apr;14(4):265-73. Review. PubMed PMID: 12679730.

41: Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42(4):361-72. Review. PubMed PMID: 12648026.

42: Nagykálnai T. [Selective estrogen receptor modulators (SERMs) in the practice]. Magy Onkol. 2002;46(2):165-75. Epub 2002 Aug 29. Review. Hungarian. PubMed PMID: 12202896.

43: Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther. 2002;24 Suppl C:C43-57. Review. PubMed PMID: 12117075.

44: Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther. 2002;24 Suppl C:C3-25. Review. PubMed PMID: 12117074.

45: Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther. 2002;24 Suppl C:C26-42. Review. PubMed PMID: 12117073.

46: Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002 Jul;43(1):63-76. Review. PubMed PMID: 12098608.

47: Alba E, Ragonesi G, Colla F, Mazzoleni A, Farina C. [Antiestrogen therapy in the treatment of breast neoplasms]. Minerva Ginecol. 2002 Jun;54(3):245-51. Review. Italian. PubMed PMID: 12063440.

48: Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001 Dec;7(12 Suppl):4402s-4410s; discussion 4411s-4412s. Review. PubMed PMID: 11916232.

49: Johnston SR. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res. 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s. Review. PubMed PMID: 11916228.

50: Gajdos C, Jordan VC. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin Breast Cancer. 2002 Jan;2(4):272-81. Review. PubMed PMID: 11899358.

51: Hirsimäki P, Aaltonen A, Mäntylä E. Toxicity of antiestrogens. Breast J. 2002 Mar-Apr;8(2):92-6. Review. PubMed PMID: 11896754.

52: Barrón-González A, Arias-Martínez J, Castro-Romero I. [Antiestrogens: mechanism of action and clinical applications]. Salud Publica Mex. 2001 Nov-Dec;43(6):577-84. Review. Spanish. PubMed PMID: 11816234.

53: Wolff AC, Davidson NE. Use of SERMs for the adjuvant therapy of early-stage breast cancer. Ann N Y Acad Sci. 2001 Dec;949:80-8. Review. PubMed PMID: 11795384.

54: Thiebaud D, Secrest RJ. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. Reprod Fertil Dev. 2001;13(4):331-6. Review. PubMed PMID: 11800172.

55: Curtis MG. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf. 2001;24(14):1039-53. Review. PubMed PMID: 11735660.

56: Sonoo H, Kurebayashi J. [Endocrine therapy for advanced or recurrent breast cancer]. Gan To Kagaku Ryoho. 2001 Jul;28(7):909-16. Review. Japanese. PubMed PMID: 11478139.

57: Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Järveläinen HA, Ramchandani VA. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):40S-45S. Review. PubMed PMID: 11391047.

58: McGinn K, Moore J. Metastatic breast cancer: understanding current management options. Oncol Nurs Forum. 2001 Apr;28(3):507-12; quiz 513-4. Review. Erratum in: Oncol Nurs Forum 2001 Jun;28(5):794. PubMed PMID: 11338758.

59: White IN. Anti-oestrogenic drugs and endometrial cancers. Toxicol Lett. 2001 Mar 31;120(1-3):21-9. Review. PubMed PMID: 11323158.

60: Taras TL, Wurz GT, Linares GR, DeGregorio MW. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet. 2000 Nov;39(5):327-34. Review. PubMed PMID: 11108432.

61: Kimura M. [Antiestrogenic agents for treatment of advanced breast cancers]. Nippon Rinsho. 2000 Apr;58 Suppl:311-6. Review. Japanese. PubMed PMID: 11026011.

62: Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000 May-Jun;6(3):212-24. Review. PubMed PMID: 10874566.

63: Plouffe L Jr. Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig. 2000 Jan-Feb;7(1 Suppl):S38-46. Review. PubMed PMID: 10732328.

64: McDonnell DP. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen. J Soc Gynecol Investig. 2000 Jan-Feb;7(1 Suppl):S10-5. Review. PubMed PMID: 10732322.

65: Jirecek S, Pavo I, Huber JC. [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues]. Gynakol Geburtshilfliche Rundsch. 1999;39(4):184-90. Review. German. PubMed PMID: 10629380.

66: Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999 Nov;37(5):399-431. Review. Erratum in: Clin Pharmacokinet 2000 Jun;38(6):491. PubMed PMID: 10589374.

67: Bus PJ, Verspaget HW, van Krieken JH, de Roos A, Keizer HJ, Bemelman WA, Vasen HF, Lamers CB, Griffioen G. Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literature. Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1179-83. Review. PubMed PMID: 10524651.

68: Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: a look ahead. Drugs. 1999 May;57(5):653-63. Review. PubMed PMID: 10353293.

69: Tominaga T. [Recent development of oral anti-cancer drugs for breast cancer]. Gan To Kagaku Ryoho. 1999 Feb;26(3):301-7. Review. Japanese. PubMed PMID: 10065092.

70: Coates A. International Breast Cancer Study Group trials. Recent Results Cancer Res. 1998;152:429-40. Review. PubMed PMID: 9928577.

71: DeGregorio MW, Taras TL. Hormone replacement therapy and breast cancer: revisiting the issues. J Am Pharm Assoc (Wash). 1998 Nov-Dec;38(6):738-44; quiz 744-6. Review. PubMed PMID: 9861792.

72: Powles TJ. Status of antiestrogen breast cancer prevention trials. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):28-31. Review. PubMed PMID: 9556788.

73: Holli K. Adjuvant trials of toremifene vs tamoxifen: the European experience. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7. Review. PubMed PMID: 9556787.

74: Smith LL, White IN. Antiestrogen therapy: uncertainties and risk assessment. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):14-22. Review. PubMed PMID: 9556786.

75: Vogel CL. Phase II and III clinical trials of toremifene for metastatic breast cancer. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):9-13. Review. PubMed PMID: 9556785.

76: Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol. 1998 Jan;16(1):348-53. Review. PubMed PMID: 9440763.

77: Mäenpää JU, Ala-Fossi SL. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging. 1997 Oct;11(4):261-70. Review. PubMed PMID: 9342556.

78: Wiseman LR, Goa KL. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs. 1997 Jul;54(1):141-60. Review. PubMed PMID: 9211086.

79: Lindner DJ, Kalvakolanu DV, Borden EC. Increasing effectiveness of interferon-alpha for malignancies. Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-99-S9-104. Review. PubMed PMID: 9208879.

80: Williams GM, Jeffrey AM. Safety assessment of tamoxifen and toremifene. Oncology (Williston Park). 1997 May;11(5 Suppl 4):41-7. Review. PubMed PMID: 9165506.

81: Gams R. Phase III trials of toremifene vs tamoxifen. Oncology (Williston Park). 1997 May;11(5 Suppl 4):23-8. Review. PubMed PMID: 9165503.

82: Hamm JT. Phase I and II studies of toremifene. Oncology (Williston Park). 1997 May;11(5 Suppl 4):19-22. Review. PubMed PMID: 9165502.

83: Valavaara R. Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Williston Park). 1997 May;11(5 Suppl 4):14-8. Review. PubMed PMID: 9165501.

84: Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol. 1997 Feb;15(2):840-52. Review. PubMed PMID: 9053512.

85: Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Cancer. 1996 Apr;32A(4):576-88. Review. PubMed PMID: 8695256.

86: Toremifene. IARC Monogr Eval Carcinog Risks Hum. 1996;66:367-87. Review. PubMed PMID: 9097128.

87: Tellez C, Jordan VC. Hormonal treatment of advanced breast cancer. Surg Oncol Clin N Am. 1995 Oct;4(4):751-77. Review. PubMed PMID: 8535909.

88: Iino Y, Takei H, Morishita Y. [Adjuvant endocrine therapy for breast cancer]. Gan To Kagaku Ryoho. 1995 Apr;22 Suppl 1:81-7. Review. Japanese. PubMed PMID: 7747997.

89: Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl. 1995;22:51-7. Review. PubMed PMID: 8538210.

90: Timmons MJ. Fibromatosis, desmoids, fibroblasts, and tamoxifen. Br J Plast Surg. 1994 Jul;47(5):378-80. Review. PubMed PMID: 8087379.

91: Iino Y, Morishita Y. [Breast cancer--tamoxifen and tamoxifen analogues for the treatment of breast cancer]. Nippon Rinsho. 1994 Mar;52(3):797-803. Review. Japanese. PubMed PMID: 8164385.

92: Lynch HT, Fitzgibbons R Jr, Chong S, Cavalieri J, Lynch J, Wallace F, Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum. 1994 Mar;37(3):260-7. Review. PubMed PMID: 8137673.

93: Schneider PG, Jackisch C, Brandt B. Endocrine management of breast cancer. Int J Fertil Menopausal Stud. 1994;39 Suppl 2:115-27. Review. PubMed PMID: 7874188.

94: Koester SK, Maenpaa JU, Wiebe VJ, Baker WJ, Wurz GT, Seymour RC, Koehler RE, DeGregorio MW. Flow cytometry: potential utility in monitoring drug effects in breast cancer. Breast Cancer Res Treat. 1994;32(1):57-65. Review. PubMed PMID: 7819587.

95: Sonoo H, Kurebayashi J. [Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen]. Gan To Kagaku Ryoho. 1993 Dec;20(15):2289-99. Review. Japanese. PubMed PMID: 8259841.

96: Izuo M. [New drugs in endocrine treatment of breast cancer]. Nippon Naibunpi Gakkai Zasshi. 1992 May 20;68(5):538-49. Review. Japanese. PubMed PMID: 1322843.

97: Kangas L. Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol. 1992;31(2):143-6. Review. PubMed PMID: 1535778.

98: Rubens RD. Treatment of metastatic breast cancer and its complications. Curr Opin Oncol. 1991 Dec;3(6):1029-34. Review. PubMed PMID: 1668827.

99: Számel I, Hindy I, Vincze B, Ady N, Eckhardt S. [The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients]. Orv Hetil. 1991 Mar 31;132(13):683-6. Review. Hungarian. PubMed PMID: 1826556.

100: Valavaara R, Tuominen J, Johansson R. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer. 1990 Dec 1;66(11):2264-9. Review. PubMed PMID: 2147123.

101: Robinson SP, Parker CJ, Jordan VC. Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S9-17. Review. PubMed PMID: 2149286.

102: Valavaara R. Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S31-5. Review. PubMed PMID: 2149283.

103: Kangas L. Introduction to toremifene. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S3-7. Review. PubMed PMID: 2149282.

104: Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem. 1990 Jun 22;36(3):191-5. Review. PubMed PMID: 2142231.

105: Jordan VC, Tormey DC. Antiestrogen therapy for breast cancer: current strategies and future prospects. Cancer Treat Res. 1988;39:97-110. Review. PubMed PMID: 2908611.